Semaglutide Compounding Under Scrutiny: The Novo Nordisk Supply Update

The GLP-1 receptor agonist market has become one of the most contested spaces in pharmaceutical history, with semaglutide — the active ingredient in Ozempic and Wegovy — at the center of a collision between pharmaceutical patents, compounding pharmacy access, drug shortage policy, and consumer demand for affordable weight-loss medication. What began as a straightforward drug shortage has evolved into a legal, regulatory, and public health question with no clean answers.

The shortage that opened the door

When demand for semaglutide surged beginning in 2022, Novo Nordisk could not keep up. The FDA placed semaglutide on its official Drug Shortages Database, a designation that triggered an important legal consequence: under Section 503A of the Federal Food, Drug, and Cosmetic Act (FDCA), licensed compounding pharmacies are permitted to compound copies of drugs that are on the FDA's shortage list, provided they meet certain conditions — including a valid patient-specific prescription.^[1]

Compounding pharmacies filled the gap. The economics were compelling: branded Wegovy costs approximately $1,349 per month without insurance, while compounded semaglutide was available for $99 to $500 per month through telehealth platforms and compounding networks. For patients without insurance coverage for weight management — which remains common — compounded versions were often the only financially viable option.^[3]

The result was a rapid expansion of the compounded GLP-1 market, estimated at over $1 billion annually by some industry analysts. Dozens of telehealth companies launched or pivoted to offer compounded semaglutide prescriptions, and compounding pharmacies scaled production to meet demand.

Supply normalizes, legal pressure rises

Novo Nordisk has invested heavily in manufacturing capacity, and supply has gradually caught up with demand. In February 2026, the FDA removed certain semaglutide dosage forms from the shortage list — a move that directly narrows the legal basis under which compounders had been operating.^[1]

The company has also pursued aggressive legal action. According to court filings and public statements, Novo Nordisk has filed reportedly more than 130 lawsuits against compounding pharmacies, telehealth platforms, and resellers, alleging patent infringement and FDCA violations.^[6] The legal theory is straightforward: semaglutide is a patented molecule, and compounding it without authorization infringes those patents. Separately, the FDA's position is that once a drug is no longer in shortage, the 503A compounding exemption no longer applies.

Not everyone agrees with this framing. Trade organizations like the Professional Compounding Centers of America (PCCA) have argued that individual patient needs — such as allergies to inactive ingredients in branded products, or the need for non-standard dosage forms — still justify compounding under 503A, regardless of shortage status.^[5] The legal question of where shortage-based compounding ends and patient-need-based compounding begins remains unresolved.

The quality question

Alongside the legal dispute, the FDA has raised substantive safety concerns about compounded GLP-1 products. As of April 2025, the agency had documented over 520 adverse event reports associated with compounded semaglutide, including approximately 10 deaths and 100 hospitalizations.^[4]

The most common problems fall into three categories:

Dosing errors. Compounded semaglutide typically comes in multi-dose vials that require patients to measure their own doses using insulin syringes. Confusion between milligrams, milliliters, and "units" has led to documented overdoses of 5 to 20 times the intended amount. FDA-approved pens deliver pre-measured doses, eliminating this variable.

Sterility failures. Compounding pharmacies operate under different manufacturing standards than FDA-approved drug manufacturers. The FDA has sent over 50 warning letters to GLP-1 compounders for violations including inadequate sterility testing, contamination, and improper labeling.

Salt form differences. Many compounders use semaglutide sodium or semaglutide acetate rather than the semaglutide base used in Ozempic and Wegovy. The FDA has explicitly stated that these are different chemical entities, and their bioequivalence has not been established.^[7] In practical terms, this means a patient switching between compounded and branded semaglutide — or between two different compounders — may receive meaningfully different pharmacological exposure even at the "same" dose.

What happens next

The situation is evolving on multiple fronts, and several scenarios are possible.

Full removal from the shortage list. If the FDA removes all semaglutide dosage forms from the shortage list, the legal basis for shortage-based compounding disappears entirely. Compounders would need to demonstrate individual patient-specific clinical need under 503A — a much higher bar than the current shortage exemption.

Continued compounding under uncertainty. Some compounders may continue operating while legal challenges play out, particularly if courts issue injunctions or if the shortage status fluctuates. This creates a gray period where patients may have access but face increasing regulatory risk.

Legislative action. Several bills have been introduced in Congress addressing compounding access for GLP-1 drugs. The political dynamics are complex: pharmaceutical companies have strong lobbying power, but the affordability argument resonates with voters and has bipartisan appeal.

The tirzepatide parallel. A nearly identical situation is unfolding with tirzepatide (Mounjaro/Zepbound), manufactured by Eli Lilly. Tirzepatide has faced its own shortage-to-enforcement cycle, and the legal and regulatory outcomes for semaglutide will likely set precedent for tirzepatide as well.

What this means for you

If you are currently using compounded semaglutide, here are the practical considerations:

Talk to your prescriber. Your physician or telehealth provider should be aware of the changing regulatory landscape and can help you understand your options — whether that means transitioning to branded products, exploring insurance coverage, or evaluating whether continued compounding is appropriate for your specific situation.

Understand the regulatory timeline. The shortage list status can change, and legal proceedings take time. The transition is not happening overnight, but the direction is clear: the window for broad compounding access is narrowing.

Don't stockpile. Semaglutide has a limited shelf life, and hoarding compounded product introduces storage and potency risks. If your supply is interrupted, your prescriber can help manage the transition — including gradual dose reduction if needed to minimize rebound effects.

Know your options. Manufacturer savings programs, insurance appeals, and the potential expansion of Medicare/Medicaid coverage (expected April 2026) may make branded products more accessible than you expect. The cost gap between compounded and branded semaglutide, while still significant, is narrowing through these channels.

For a deeper look at semaglutide's mechanism, clinical evidence, and safety profile, see our full semaglutide profile.

---

References

1. [1]

   U.S. Food and Drug Administration. “FDA Drug Shortages Database — Semaglutide injection.” 2026. Link

   Official FDA drug shortage database. Semaglutide shortage status updated February 2026. Some dosage forms removed from shortage list while others remain under review.

2. [2]

   Novo Nordisk A/S. “Annual Report 2025 — 10-K Filing, SEC.” 2025. Link

   SEC-filed annual report. Includes production capacity expansion details, patent enforcement disclosures, and GLP-1 supply projections.

3. [3]

   IQVIA Institute for Human Data Science. “GLP-1 receptor agonist market trends — U.S. spending and utilization report.” 2025. Link

   Industry-standard pharmaceutical market analytics. Estimated $24B+ in U.S. GLP-1 spending for 2025.

4. [4]

   U.S. Food and Drug Administration. “FDA's concerns with unapproved GLP-1 drugs used for weight loss.” 2025. Link

   FDA safety communication documenting adverse events from compounded semaglutide and tirzepatide, including dosing errors, sterility failures, and hospitalizations.

5. [5]

   Professional Compounding Centers of America (PCCA). “PCCA statement on FDA drug shortage list and compounding access.” 2025. Link

   Trade organization representing compounding pharmacies. Advocates for continued compounding access under FDCA Section 503A when clinical need exists.

6. [6]

   Novo Nordisk A/S. “Patent infringement and FDCA enforcement actions against compounding entities.” 2025. Link

   Aggregated from court filings and Novo Nordisk public statements. 130+ lawsuits filed against compounders and resellers of semaglutide products as of early 2026.

7. [7]

   U.S. Food and Drug Administration. “Compounded drugs containing semaglutide sodium — FDA advisory.” 2025. Link

   FDA advisory clarifying that semaglutide sodium is a different salt form than the active ingredient in Ozempic/Wegovy. Bioequivalence has not been established.

---

---

Related content

Peptide

Semaglutide

Research profile covering mechanism, evidence, and clinical context.

Peptide

Tirzepatide

The dual GIP/GLP-1 agonist facing similar compounding questions.

News

What Are Compounding Pharmacies?

How compounding pharmacies work and why they matter for peptide access.

Guide

How to Evaluate a Peptide Clinic

A scorecard for evaluating providers — especially relevant as compounding access shifts.

News

FDA Enforcement and the Gray Market

The broader regulatory context behind the scrutiny on compounded semaglutide.